511 related articles for article (PubMed ID: 26362997)
21. Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Maglio ME; Lonial S; San-Miguel J
Pharmacol Res; 2017 Mar; 117():185-191. PubMed ID: 27884726
[TBL] [Abstract][Full Text] [Related]
22. Panobinostat: first global approval.
Garnock-Jones KP
Drugs; 2015 Apr; 75(6):695-704. PubMed ID: 25837990
[TBL] [Abstract][Full Text] [Related]
23. Panobinostat (Farydak) for multiple myeloma.
Med Lett Drugs Ther; 2015 Aug; 57(1475):e118-9. PubMed ID: 26262884
[No Abstract] [Full Text] [Related]
24. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
Richardson PG; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Corrado C; Binlich F; San-Miguel JF
Blood; 2016 Feb; 127(6):713-21. PubMed ID: 26631116
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Laubach JP; Schjesvold F; Mariz M; Dimopoulos MA; Lech-Maranda E; Spicka I; Hungria VTM; Shelekhova T; Abdo A; Jacobasch L; Polprasert C; Hájek R; Illés Á; Wróbel T; Sureda A; Beksac M; Gonçalves IZ; Bladé J; Rajkumar SV; Chari A; Lonial S; Spencer A; Maison-Blanche P; Moreau P; San-Miguel JF; Richardson PG
Lancet Oncol; 2021 Jan; 22(1):142-154. PubMed ID: 33301738
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
[TBL] [Abstract][Full Text] [Related]
27. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
Richardson PG; Schlossman RL; Alsina M; Weber DM; Coutre SE; Gasparetto C; Mukhopadhyay S; Ondovik MS; Khan M; Paley CS; Lonial S
Blood; 2013 Oct; 122(14):2331-7. PubMed ID: 23950178
[TBL] [Abstract][Full Text] [Related]
28. [Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].
Stegmann DA
Med Monatsschr Pharm; 2016 Apr; 39(4):142-7. PubMed ID: 27209894
[TBL] [Abstract][Full Text] [Related]
29. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Cea M; Cagnetta A; Gobbi M; Patrone F; Richardson PG; Hideshima T; Anderson KC
Curr Pharm Des; 2013; 19(4):734-44. PubMed ID: 23016853
[TBL] [Abstract][Full Text] [Related]
30. Panobinostat approved for multiple myeloma.
Cancer Discov; 2015 May; 5(5):OF4. PubMed ID: 25802326
[No Abstract] [Full Text] [Related]
31. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
[TBL] [Abstract][Full Text] [Related]
32. Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Majer I; van de Wetering G; Polanyi Z; Krishna A; Gray E; Roy A
Appl Health Econ Health Policy; 2017 Feb; 15(1):45-55. PubMed ID: 27550239
[TBL] [Abstract][Full Text] [Related]
33. Panobinostat: a review of trial results and future prospects in multiple myeloma.
Libby EN; Becker PS; Burwick N; Green DJ; Holmberg L; Bensinger WI
Expert Rev Hematol; 2015 Feb; 8(1):9-18. PubMed ID: 25410127
[TBL] [Abstract][Full Text] [Related]
34. An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma.
Hansen VL; Coleman M; Elkins S; Letzer JP; Levy MY; Seneviratne L; Rine J; White M; Kuriakose ET
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):400-407.e1. PubMed ID: 29656050
[TBL] [Abstract][Full Text] [Related]
35. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Moore DC; Arnall JR; Harvey RD
J Oncol Pharm Pract; 2019 Apr; 25(3):613-622. PubMed ID: 30060709
[TBL] [Abstract][Full Text] [Related]
36. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
37. The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.
Cassier PA; Floquet A; Penel N; Derbel O; Bui N'guyen B; Guastalla JP; Pissaloux D; Treilleux I; Saba CE; Blay JY; Ray-Coquard I
Ann Oncol; 2014 May; 25(5):1074-5. PubMed ID: 24651409
[No Abstract] [Full Text] [Related]
38. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
39. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
San-Miguel JF; Hungria VTM; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Na Nakorn T; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Salwender H; Sopala M; Redhu S; Paul S; Corrado C; Richardson PG
Br J Haematol; 2017 Oct; 179(1):66-74. PubMed ID: 28653400
[TBL] [Abstract][Full Text] [Related]
40. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
